Dongguangyang Pharma’s "Key Technological Innovations and Industrialization of Anti-Infective Drug R&D" Project Awarded First Prize in Guangdong Provincial Science and Technology Progress Awards

Guangzhou, China – Guangdong Dongguangyang Pharmaceutical Co., Ltd. (referred to as “Dongguangyang Pharma”) has been honored with the First Prize of the 2023 Guangdong Provincial Science and Technology Progress Award for its groundbreaking project, Key Technological Innovations and Industrialization of Anti-Infective Drug R&D. This accolade, granted by the Department of Science and Technology of Guangdong Province, recognizes exceptional contributions to scientific advancement and societal impact.

Project Significance

Infectious diseases account for over 25% of global mortality (WHO, 2020), with annual healthcare costs for moderate-to-severe infections exceeding $570 billion. Viral hepatitis and influenza rank among China’s most prevalent infectious diseases, while antimicrobial resistance and severe bacterial infections pose life-threatening risks. To address these challenges, Dongguangyang Pharma has pioneered innovations in three critical areas:

1. Original Drug Development: Advanced novel anti-infective therapies targeting unmet clinical needs.
2. Preclinical Evaluation: Established cutting-edge in vitro/vivo models for drug efficacy and safety assessment.
3. Manufacturing Breakthroughs: Optimized synthesis and scalable production processes for global supply.

Achievements

• Intellectual Property: 160 authorized patents (90 international) and 37 peer-reviewed publications.
• Pipeline Milestones: 9 Class 1 innovative drugs in clinical trials; Oseltamivir (branded as Kewei)—a WHO-recommended influenza treatment—holds over 50% global market share in erythromycin APIs, supplying top-tier firms including Abbott and Pfizer.
• Commercial Impact: Over RMB 6.6 billion in revenue (past three years); Kewei series products adopted by 1,000+ tertiary hospitals, including Peking Union Medical College Hospital and Sun Yat-sen University-affiliated institutions.

Corporate Vision

Since its founding in 2003, Dongguangyang Pharma has prioritized R&D-driven growth, emerging as a global pharmaceutical leader with end-to-end capabilities in discovery, development, and commercialization. The company’s pipeline spans infectious diseases, chronic conditions, and oncology, featuring 45 Class 1 innovative drugs, 3 NDAs under review, and 10 candidates in Phase II/III trials.

Mr. Jiang Juncai, Chairman, emphasized: “Our mission is to deliver transformative medicines that safeguard public health. This award reaffirms our commitment to innovation and societal responsibility, aligning with China’s ‘Healthy Nation 2030’ vision.”